SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PTGX reported Third Quarter 2026 results. The stock moved -2.4% on the print.
PTGXearnings

Earnings reactions, page 5

Protagonist Therapeutics, Inc. (PTGX) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • License and collaboration revenue was $274.4 million for the third quarter of 2026, compared to $4.7 million for the third quarter of 2025.
  • Research and development expense was $41.3 million for the third quarter of 2026, compared to $40.0 million for the third quarter of 2025.
  • General and administrative expense was $13.7 million for the third quarter of 2026, compared to $11.1 million for the third quarter of 2025.
  • Net income was $220.0 million, or $3.07 per diluted share, for the third quarter of 2026, compared to a net loss of $39.3 million, or $0.62 per diluted share, for the third quarter of 2025.
  • Cash, cash equivalents and marketable securities totaled $834.6 million as of September 30, 2026, compared to $646.0 million as of December 31, 2025.

Guidance

  • The Company expects R&D expenses to increase for the remainder of the year as compared to the prior quarters in 2026.

Price and volatility reaction

The stock moved -2.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -19.7 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release135.262026-11-05
Close after release132.042026-11-06
Realised move-2.4%close to close
30d ATM IV change-19.7 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →